PE20131394A1 - Monohidrato de derivados de aza-adamantano - Google Patents

Monohidrato de derivados de aza-adamantano

Info

Publication number
PE20131394A1
PE20131394A1 PE2013000540A PE2013000540A PE20131394A1 PE 20131394 A1 PE20131394 A1 PE 20131394A1 PE 2013000540 A PE2013000540 A PE 2013000540A PE 2013000540 A PE2013000540 A PE 2013000540A PE 20131394 A1 PE20131394 A1 PE 20131394A1
Authority
PE
Peru
Prior art keywords
temperature
propanol
adjust
solution
monohydrate
Prior art date
Application number
PE2013000540A
Other languages
English (en)
Inventor
Shuang Chen
James J Napier
Geoff G Z Zhang
J Brackemeyer Paul
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44736085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20131394A1 publication Critical patent/PE20131394A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DE UN DERIVADO DE AZA-ADAMANTANO TAL COMO EL MONOHIDRATO DEL CITRATO DIACIDO DE (4S)-4-(5-FENIL-1,3,4-TIADIAZOL-2-ILOXI)-1-AZATRICICLO[3.3.1.1 3,7]DECANO QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X EN POLVO QUE COMPRENDE LOS SIGUIENTES PICOS EXPRESADOS EN GRADOS 2 THETA: 8.4 � 0.20, 11.3 � 0.20, 14.2 � 0.20, 15.5 � 0.20, 16.4 � 0.20, 16.6 � 0.20, 17.2 � 0.20, 19.7 � 0.20, 20.7 � 0.20, 21.0 � 0.20, 21.2 � 0.20, 21.6 � 0.20, 24.8 � 0.20 Y 26.9 � 0.20. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DE DICHA FORMA CRISTALINA QUE COMPRENDE: A) DISOLVER (4S)-4-(5-FENIL-1,3,4-TIADIAZOL-2-ILOXI)-1-AZATRICICLO[3.3.1.1 3,7]DECANO EN UNA MEZCLA DE 2-PROPANOL Y AGUA A UNA TEMPERATURA DE 65 A 85 �C; B) AJUSTAR LA TEMPERATURA DE LA SOLUCION A UNA TEMPERATURA DE 55 A 75 �C; C) AGREGAR UN SOLVENTE ADICIONAL A LA SOLUCION TAL COMO 2-PROPANOL Y MEZCLAR; D) AJUSTAR LA TEMPERATURA DE LAS SOLUCIONES ENTRE 30 Y 50 �C; E) AGREGAR UN SOLVENTE ADICIONAL TAL COMO 2-PROPANOL A LA SOLUCION; F) MANTENER LA LECHADA A UNA TEMPERATURA ENTRE 30 Y 50 �C; G) AJUSTAR LA TEMPERATURA DE LA LECHADA ENTRE -5 Y 15 �C; H) MEZCLAR LA LECHADA POR UNA HORA; E I) RECUPERAR EL MONOHIDRATO CRISTALINO. DICHA FORMA CRISTALINA ES MODULADOR DE LOS RECEPTORES NICOTINICOS DE ACETILCOLINA nAChR a7 Y a4B2, SIENDO UTIL EN EL TRATAMIENTO DE MAL DE ALZHEIMER (AD), DETERIORO COGNITIVO LEVE, ESQUIZOFRENIA, DEMENCIA SENIL
PE2013000540A 2010-09-23 2011-09-21 Monohidrato de derivados de aza-adamantano PE20131394A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38567410P 2010-09-23 2010-09-23

Publications (1)

Publication Number Publication Date
PE20131394A1 true PE20131394A1 (es) 2014-01-11

Family

ID=44736085

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000540A PE20131394A1 (es) 2010-09-23 2011-09-21 Monohidrato de derivados de aza-adamantano

Country Status (24)

Country Link
US (2) US9464078B2 (es)
EP (1) EP2619205B1 (es)
JP (2) JP2013537912A (es)
KR (1) KR20130108586A (es)
CN (2) CN106074548A (es)
AR (1) AR083100A1 (es)
AU (1) AU2011305462B2 (es)
BR (2) BR112013005434A2 (es)
CA (1) CA2809675A1 (es)
CL (2) CL2013000756A1 (es)
CO (1) CO6720965A2 (es)
CR (2) CR20130169A (es)
DO (2) DOP2013000064A (es)
EC (1) ECSP13012575A (es)
GT (1) GT201300064A (es)
MX (1) MX2013003344A (es)
NZ (2) NZ707955A (es)
PE (1) PE20131394A1 (es)
RU (2) RU2579121C2 (es)
SG (2) SG188307A1 (es)
TW (2) TW201626996A (es)
UA (1) UA110802C2 (es)
UY (1) UY33628A (es)
WO (1) WO2012040404A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
US20130317055A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US8969562B2 (en) 2013-03-12 2015-03-03 Abbvie, Inc. Azaadamantane formate ester and process for preparing azaadamantane derivatives
JP2016540001A (ja) * 2013-12-13 2016-12-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ステロイド様化合物の多形形態並びにその製造方法及びその用途
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
JP2018516973A (ja) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
JP2018523707A (ja) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514006A1 (fr) 1981-10-05 1983-04-08 Nativelle Sa Ets Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique
EP0088484A1 (en) 1982-02-04 1983-09-14 Fbc Limited Herbicidal thiadiazolyl N-aminoureas
GB8523211D0 (en) 1985-09-19 1985-10-23 Beecham Group Plc Compounds
US4950759A (en) 1988-07-07 1990-08-21 Duphar International Research B.V. Substituted 1,7-annelated 1H-indazoles
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
AU1752792A (en) 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5280028A (en) 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5840903A (en) 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
JP3235913B2 (ja) 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
US5821371A (en) 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5852037A (en) 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
WO1997020819A1 (en) 1995-12-06 1997-06-12 Eli Lilly And Company Composition for treating pain
WO1998027983A1 (en) 1996-12-20 1998-07-02 Novo Nordisk A/S A method of treating hypercholesterolemia and related disorders
US7732163B2 (en) 1997-08-21 2010-06-08 Board Of Trustees Of The University Of Arkansas Extracellular serine protease
US8236500B2 (en) 1997-10-23 2012-08-07 The United States Of America, As Represented By The Department Of Veterans Affairs Promoter variants of the alpha-7 nicotinic acetylcholine receptor
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
ATE213246T1 (de) 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
WO1999051602A1 (en) 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them
US5986100A (en) 1998-04-02 1999-11-16 Crooks; Peter Anthony Pharmaceutical compositions and methods for use
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US6057446A (en) 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US6093724A (en) 1998-08-18 2000-07-25 Ucb, S.A. Muscarinic agonists and antagonists
AU774867B2 (en) 1999-05-04 2004-07-08 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
KR20020010670A (ko) 1999-05-24 2002-02-04 추후제출 니코틴 콜린성 수용체를 활성화시킬 수 있는 아릴치환된알킬아민
WO2001040261A1 (en) 1999-12-01 2001-06-07 Ortho-Mcneil Pharmaceutical, Inc. Method of diagnosing neurodegenerative disease
WO2001082978A2 (en) 2000-05-01 2001-11-08 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
US7060699B2 (en) 2000-07-04 2006-06-13 Neurosearch A/S Aryl and heteroaryl diazabicycloalkanes, their preparation and use
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
JP4225787B2 (ja) 2001-03-27 2009-02-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｎ−アリール環状アミン誘導体およびそれを有効成分として含有する医薬
US20030124028A1 (en) 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
CA2470567A1 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
NZ535642A (en) 2002-05-07 2006-10-27 Neurosearch As Novel diazabicyclic biaryl derivatives
US7049374B2 (en) 2002-07-18 2006-05-23 Chevron U.S.A. Inc. Heterodiamondoids
WO2004016608A1 (en) 2002-08-14 2004-02-26 Neurosearch A/S Novel quinuclidine derivatives and their use
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2004229237B2 (en) 2003-04-16 2009-06-04 Merck Serono Sa Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
JP2005232071A (ja) 2004-02-19 2005-09-02 Kanto Chem Co Inc ピラゾール誘導体
EP1747206A1 (en) 2004-04-29 2007-01-31 Abbott Laboratories Amino-tetrazoles analogues and methods of use
ATE417837T1 (de) 2004-05-24 2009-01-15 Amgen Inc Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
EP1781265B1 (en) 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
CA2584836A1 (en) 2004-10-15 2006-04-20 Neurosearch A/S Novel azabicyclic aryl derivatives and their medical use
NZ553622A (en) 2004-10-20 2010-08-27 Neurosearch As Novel diazabicyclic aryl derivatives and their medical use
CN1922176A (zh) 2004-12-10 2007-02-28 艾博特公司 稠合的双环杂环取代的奎宁环衍生物
US8906360B2 (en) 2005-07-22 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US20090093403A1 (en) 2007-03-01 2009-04-09 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
WO2007065892A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
WO2008002594A2 (en) 2006-06-27 2008-01-03 Neuroprotection For Life Corp. Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
FR2905009A1 (fr) 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US20100152108A1 (en) 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN101541792A (zh) * 2006-11-06 2009-09-23 艾博特公司 氮杂金刚烷衍生物和应用方法
CA2678193A1 (en) 2007-02-09 2008-08-14 Astellas Pharma Inc. Aza-bridged-ring compound
WO2008112177A2 (en) 2007-03-08 2008-09-18 Genizon Biosciences, Inc. Genemap of the human genes associated with schizophrenia
JP5566698B2 (ja) 2007-03-23 2014-08-06 アッヴィ・インコーポレイテッド アザアダマンタンエステルおよびカーバメート誘導体ならびにそれらの使用方法
CN101772346B (zh) 2007-04-02 2014-05-07 帕金森氏病研究院 用于降低治疗副作用的方法和组合物
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
WO2009058120A1 (en) 2007-11-02 2009-05-07 Sri International Nicotinic acetylcholine receptor modulators
EP2221306B1 (en) 2007-11-20 2016-04-13 Nissan Chemical Industries, Ltd. Method for producing 2-azaadamantane
DE102007058504A1 (de) 2007-12-05 2009-07-09 Acino Ag Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
MX2010008875A (es) 2008-02-13 2010-08-31 Targacept Inc Agonistas nicotinicos alfa 7 y antipsicoticos.
US20090239901A1 (en) 2008-03-19 2009-09-24 Merouane Bencherif Method and compositions for treatment of cerebral malaria
US20110098312A1 (en) 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
FR2931677B1 (fr) 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
EP2294082A4 (en) 2008-06-13 2011-07-13 Ct For Addiction And Mental Health COMPOSITIONS AND METHOD FOR MODULATING THE NICOTIN / NMDA RECEPTOR FUNCTION
WO2010030887A1 (en) 2008-09-11 2010-03-18 Catholic Healthcare West Nicotinic attenuation of cns inflammation and autoimmunity
EP2344636B1 (en) 2008-10-09 2017-12-06 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
JP5657556B2 (ja) 2008-11-11 2015-01-21 ターガセプト，インコーポレイテッド α７選択的リガンドを用いる治療
US20110312894A1 (en) 2009-01-28 2011-12-22 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases
US20120149691A1 (en) 2009-07-31 2012-06-14 Biocryst Pharmaceuticals, Inc. Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors
WO2011022467A2 (en) 2009-08-21 2011-02-24 University Of Florida Research Foundation, Inc. Controlled-release formulations of anabaseine compounds and uses thereof
US20120270844A1 (en) 2009-10-09 2012-10-25 Afraxis, Inc. Methods for treating alzheimer's disease
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
CR20130169A (es) 2013-06-12
NZ609761A (en) 2015-10-30
ECSP13012575A (es) 2013-07-31
TW201626996A (zh) 2016-08-01
CN106074548A (zh) 2016-11-09
UA110802C2 (uk) 2016-02-25
GT201300064A (es) 2014-07-11
US9464078B2 (en) 2016-10-11
CN103180321A (zh) 2013-06-26
BR122014023207A2 (pt) 2019-05-28
UY33628A (es) 2012-03-30
RU2013118560A (ru) 2014-10-27
US20150239882A1 (en) 2015-08-27
NZ707955A (en) 2016-03-31
SG2014013460A (en) 2014-09-26
CR20130594A (es) 2014-01-31
KR20130108586A (ko) 2013-10-04
JP2013537912A (ja) 2013-10-07
SG188307A1 (en) 2013-04-30
RU2016105706A (ru) 2018-11-22
CL2014000651A1 (es) 2014-09-05
RU2579121C2 (ru) 2016-03-27
MX2013003344A (es) 2013-06-28
CL2013000756A1 (es) 2013-07-12
US20120245195A1 (en) 2012-09-27
WO2012040404A1 (en) 2012-03-29
AR083100A1 (es) 2013-01-30
CO6720965A2 (es) 2013-07-31
AU2011305462B2 (en) 2015-11-26
TW201212914A (en) 2012-04-01
AU2011305462A1 (en) 2013-03-21
EP2619205B1 (en) 2017-05-17
DOP2013000249A (es) 2014-01-15
DOP2013000064A (es) 2013-07-15
BR112013005434A2 (pt) 2016-06-07
EP2619205A1 (en) 2013-07-31
CA2809675A1 (en) 2012-03-29
JP2017039764A (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
PE20131394A1 (es) Monohidrato de derivados de aza-adamantano
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
AR068840A1 (es) Moduladores del gpr40 bifenilo sustituidos y composiciones farmaceuticas que los contienen
BR112014026809A2 (pt) métodos para a síntese de etilfumaratos ativados e seu uso como intermediários
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
PE20061091A1 (es) FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRANDINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
MX2012001985A (es) Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
UY33044A (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
PE20091972A1 (es) Compuestos heterociclicos como inhibidores del factor ixa
AR077365A1 (es) Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta
PE20141204A1 (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
PE20151748A1 (es) Inhibidores de bace1
RS54361B1 (en) CORTEXOLONE-17ALFA-PROPIONATE IN CRYSTAL HYDRATE FORM IV
PE20170923A1 (es) Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
PE20081556A1 (es) Formas cristalinas de glyt1
CL2013002424A1 (es) Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.
AR116001A2 (es) Composición farmacéutica 271
AR084832A1 (es) Derivado cristalino de oxazina
MX354648B (es) Materiales zeoliticos y metodos para su preparacion utilizando compuestos alqueniltrialquilamonio.
AR081659A1 (es) Procedimiento de obtencion de la forma cristalina ii del febuxostat
PE20081167A1 (es) Sal de alisquireno
TW200833708A (en) Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
PE20170777A1 (es) Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis

Legal Events

Date Code Title Description
FC Refusal